Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Depreciation and Depletion: 2016-2023

Historic Depreciation and Depletion for Rocket Pharmaceuticals (RCKT) over the last 6 years, with Sep 2023 value amounting to $1.2 million.

  • Rocket Pharmaceuticals' Depreciation and Depletion rose 9.09% to $1.2 million in Q3 2023 from the same period last year, while for Sep 2023 it was $4.6 million, marking a year-over-year increase of 26.40%. This contributed to the annual value of $426,000 for FY2019, which is 29.09% up from last year.
  • Rocket Pharmaceuticals' Depreciation and Depletion amounted to $1.2 million in Q3 2023, which was down 0.00% from $1.2 million recorded in Q2 2023.
  • In the past 5 years, Rocket Pharmaceuticals' Depreciation and Depletion ranged from a high of $1.2 million in Q2 2023 and a low of $100,000 during Q2 2019.
  • Its 3-year average for Depreciation and Depletion is $1.0 million, with a median of $1.1 million in 2022.
  • Data for Rocket Pharmaceuticals' Depreciation and Depletion shows a peak YoY spiked of 47.98% (in 2023) over the last 5 years.
  • Rocket Pharmaceuticals' Depreciation and Depletion (Quarterly) stood at $101,000 in 2019, then remained steady at $100,000 in 2020, then reached $800,000 in 2021, then soared by 37.50% to $1.1 million in 2022, then increased by 9.09% to $1.2 million in 2023.
  • Its last three reported values are $1.2 million in Q3 2023, $1.2 million for Q2 2023, and $1.1 million during Q1 2023.